We respond to a wide range of needs from GMP-compliant nucleic acid drug manufacturing, quality evaluation, to long-term stability testing!
At Ajinomoto Bio-Pharma Services Gene Design, we conduct a wide range of activities at our contract manufacturing facility specialized in nucleic acid pharmaceuticals, including GMP-compliant active pharmaceutical ingredient production, quality evaluation, and long-term stability testing. We offer flexible support from the development of manufacturing methods for non-clinical trials to small-scale trial production and manufacturing for clinical trials. Additionally, we have an isolator-integrated freeze-drying system that allows for the production of aseptic pharmaceuticals in small batches, which is ideal for cases where you want to keep clinical trial drug production on a smaller scale. 【Features】 ■ Flexible production of development items ■ Capable of supporting manufacturing method development and small-scale trial production ■ Supply of aseptic formulations ■ Complexation technology *For more details, please refer to the external link page or feel free to contact us.
Inquire About This Product
basic information
【Other Features】 ■ Establishment of sufficient standard tests for clinical trials ■ Stability testing ・ Long-term storage tests, accelerated tests, stress tests, intermediate tests ・ Standard analysis ・ Sample storage ・ Response to written inquiries * For more details, please refer to the external link page or feel free to contact us.
Price range
Delivery Time
Applications/Examples of results
For more details, please refer to the external link page or feel free to contact us.
catalog(1)
Download All CatalogsCompany information
Ajinomoto Bio-Pharma Services and GeneDesign, Inc. are engaged in the production of oligonucleotides, incorporating the latest technologies and patent licenses from various research institutions. We supply distinctive nucleic acid materials, including the introduction of artificially modified nucleic acids and the addition of functional molecules, contributing to the development of new technologies in the gene-related fields (such as drug development, diagnostic technology development, and bio-research technology development). Currently, the demand for various synthetic nucleic acids is expanding from cell culture levels to animal testing and further to clinical trials. Our company has established a system capable of supplying everything from research reagents to investigational drugs at all scales, and we are advancing research and development daily as a company that can significantly contribute to the creation of nucleic acid pharmaceuticals and the practical application of diagnostic systems. For the future of medicine, we aim to be a company that contributes to the welfare and health of people through the development of nucleic acid manufacturing technologies, actively working on the development of next-generation nucleic acid drugs and diagnostic materials.